Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Seagen Inc.
Eli Lilly and Company
Bristol-Myers Squibb
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
NRG Oncology
Alliance for Clinical Trials in Oncology
AstraZeneca